Siegfried Holding AG
SFZN
Rangering i aksjer
#4106
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Aksjekurs
$88.34
Markedsverdi
$3.87B
Endring (1 dag)
1.68%
Endring (1 år)
-12.97%
Land
CH
Handel Siegfried Holding AG (SFZN)
Kategori
Healthcare
Antall utestående aksjer for Siegfried Holding AG (SFZN)
Antall utestående aksjer per October 2026: 0
Ifølge Siegfried Holding AG sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av October 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Siegfried Holding AG (SFZN) fra 2002 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2025 | 43.76M | 1.54% |
| 2024 | 43.09M | 1.69% |
| 2023 | 42.38M | 0.40% |
| 2022 | 42.21M | 0.37% |
| 2021 | 42.05M | 1.45% |
| 2020 | 41.45M | 0.22% |
| 2019 | 41.36M | -0.67% |
| 2018 | 41.64M | 4.91% |
| 2017 | 39.69M | 2.15% |
| 2016 | 38.86M | -1.72% |
| 2015 | 39.54M | 2.20% |
| 2014 | 38.68M | -1.37% |
| 2013 | 39.22M | 8.27% |
| 2012 | 36.23M | -1.32% |
| 2011 | 36.71M | 8.64% |
| 2010 | 33.79M | 22.52% |
| 2009 | 27.58M | -0.49% |
| 2008 | 27.71M | 0.30% |
| 2007 | 27.63M | -0.21% |
| 2006 | 27.69M | 0.25% |
| 2005 | 27.62M | 1.23% |
| 2004 | 27.28M | 0.00% |
| 2003 | 27.28M | -0.13% |
| 2002 | 27.32M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
